dm+d

Unassigned

New Medicines

Sickle cell disease - treatment of vaso-occlusive crisis

Information

New molecular entity
GlycoMimetics
GlycoMimetics

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Dec 20Based on input received from the FDA regarding rivipansel as well as feedback from key opinion leaders in sickle cell disease GlycoMimetics have determined not to proceed with the development of rivipansel as a potential treatment for the acute VOC setting [15]

Category

Small molecule glycomimetic inhibitor of E-, P- and L-selectins [2]
21 March 2015About 10,000 people in the UK have sickle cell disease. The frequency of sickle cell carriers is up to 1 in 4 in West Africans and 1 in 10 in Afro-Caribbeans. Vaso-occlusive crises is the most common type of crisis. It may be precipitated by cold, infection, dehydration, exertion or ischaemia. Often no specific cause can be found.
Sickle cell disease - treatment of vaso-occlusive crisis
Intravenous